Fig. 7
From: LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression
LRRK2G019S and LRRK2 kinase inhibition impact network progression of tau pathology. Comparisons of Pearson r, diffusion rate constant and standardized β in WT mice (a) treated with 0, 75, or 450 mg/kg MLi-2 and LRRK2G2019S mice (b) treated with 0, 75 or 450 mg/kg MLi-2. Distributions were generated for each group by obtaining 500 bootstrapped resamples and fitting the bidirectional diffusion model for each resample. Since data for the 75 mg/kg dose of MLi-2 were only available at 6 MPI, bootstrapping for each group was performed using only data from this time point. c Results of ranked robust linear regression analysis of regional tau pathology in WT mice under control treatment (0 mg/kg MLi-2) compared to LRRK2G2019S mice treated with 450 mg/kg MLi-2. Blue and red colored regions have second-generation P-values equal to 0